The FTC's long-awaited report published in July was a difficult read for the PBM industry, concluding that the six largest companies in the US market operate a concentrated market structure that ...

Tomorrow a follow-up commentary will assess the lawsuit itself. Background on PBMs Recent FTC actions portray PBM practices as harmful and anticompetitive. However, there is substantial economic ...

Nationally, criticism of PBM practices intensified over the summer with the FTC report. The PCMA pushed back, saying the ...

I say this as a Republican member of Congress who is often critical of the FTC. On this point, however, we are seemingly in lockstep. The FTC’s interim report will help pull back the curtain on ...

Reports of the FTC’s plan come just a couple of days after the regulator published its long-awaited report on the PBM sector, which concluded that their market dominance has “dire consequences ...

The FTC’s essential charge is that PBMs play insulin ... Nephron Research found that rebates accounted for only 13% of PBM profits in 2022. In any case, plans have increasingly moved to point ...

FTC Chairwoman Lina Khan, with her fellow Democratic Commissioners, recently filed a suit against the leading PBMs in an effort to undermine, or even prohibit, their use of rebates to secure ...

The Federal Trade Commission (FTC) on September 27, 2024 unexpectedly withdrew from a recently established Memorandum of Understanding (MOU) with ...

Calls for PBM reform focus on transparency and addressing monopolistic practices to improve drug affordability. The FTC's action underscores the need for urgent reforms to address PBMs' anti ...

The FTC wants details on pass-throughs of rebates ... The agency is also asking for any information in PBM company files relating to "strategies and business practices for lowering the net price ...

The FTC filed suit against UnitedHealth's Optum Rx ... "Event participants wore anti-PBM paraphernalia, including pins that vilified PBMs as 'bloodsuckers' and shirts depicting PBMs as vampires ...

So there's an incentive for a PBM to choose a more expensive drug over a less expensive one. But that can drive up a patient's cost at the pharmacy counter. Overall, the FTC says that practice ...